ATE514689T1 - 4-methyl-n-ä3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenylü-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid- monohydrochlorid- monohydrat-salz - Google Patents

4-methyl-n-ä3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenylü-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid- monohydrochlorid- monohydrat-salz

Info

Publication number
ATE514689T1
ATE514689T1 AT06787733T AT06787733T ATE514689T1 AT E514689 T1 ATE514689 T1 AT E514689T1 AT 06787733 T AT06787733 T AT 06787733T AT 06787733 T AT06787733 T AT 06787733T AT E514689 T1 ATE514689 T1 AT E514689T1
Authority
AT
Austria
Prior art keywords
methyl
phenylü
monohydrochloride
ylamino
benzamide
Prior art date
Application number
AT06787733T
Other languages
English (en)
Inventor
Paul Manley
Wen-Chung Shieh
Paul Sutton
Piotr Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37398525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE514689(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE514689T1 publication Critical patent/ATE514689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06787733T 2005-07-20 2006-07-18 4-methyl-n-ä3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenylü-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid- monohydrochlorid- monohydrat-salz ATE514689T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140605P 2005-07-20 2005-07-20
US71621305P 2005-09-12 2005-09-12
PCT/US2006/027878 WO2007015871A1 (en) 2005-07-20 2006-07-18 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
ATE514689T1 true ATE514689T1 (de) 2011-07-15

Family

ID=37398525

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06787733T ATE514689T1 (de) 2005-07-20 2006-07-18 4-methyl-n-ä3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenylü-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid- monohydrochlorid- monohydrat-salz

Country Status (33)

Country Link
US (4) US8163904B2 (de)
EP (2) EP2186808B1 (de)
JP (1) JP5129132B2 (de)
KR (3) KR20140047737A (de)
CN (1) CN102267981A (de)
AR (1) AR057467A1 (de)
AT (1) ATE514689T1 (de)
AU (2) AU2006276205C1 (de)
BR (1) BRPI0613605A2 (de)
CA (2) CA2823946C (de)
CY (1) CY1111772T1 (de)
DK (1) DK1910336T3 (de)
EC (1) ECSP088118A (de)
ES (1) ES2634291T3 (de)
GT (1) GT200600316A (de)
HR (1) HRP20110639T1 (de)
IL (1) IL187787A (de)
JO (1) JO2757B1 (de)
MA (1) MA29686B1 (de)
MX (1) MX2008000892A (de)
MY (1) MY149889A (de)
NO (1) NO341313B1 (de)
NZ (2) NZ564182A (de)
PE (1) PE20070241A1 (de)
PL (1) PL1910336T3 (de)
PT (1) PT1910336E (de)
RU (4) RU2434864C2 (de)
SG (1) SG170772A1 (de)
SI (1) SI1910336T1 (de)
TN (1) TNSN08028A1 (de)
TW (1) TWI455934B (de)
UY (1) UY29683A1 (de)
WO (1) WO2007015871A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
KR101292508B1 (ko) * 2006-04-07 2013-08-01 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
EP1923053A1 (de) 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
EP2305667A3 (de) 2008-07-17 2011-05-11 Teva Pharmaceutical Industries Ltd. Nilotinib-Zwischenprodukte und ihre Herstellung
WO2010054056A2 (en) 2008-11-05 2010-05-14 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
EP2186514B1 (de) * 2008-11-14 2016-06-29 Kinki University Behandlung von malignen Peripherienervmantel-Tumoren
KR20110132439A (ko) 2009-03-06 2011-12-07 노파르티스 아게 류신 지퍼- 및 스테릴 알파 모티프-함유 키나제 （ｚａｋ）에 의해 매개된 장애의 치료를 위한 피리미딜아미노벤즈아미드 유도체의 용도
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
US20110053968A1 (en) * 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
WO2011033307A1 (en) 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (de) 2010-01-15 2016-09-02
EP2558098A2 (de) 2010-04-16 2013-02-20 Novartis AG Behandlung von endokrinresistentem brustkrebs
EP2382976A1 (de) 2010-04-30 2011-11-02 Hiroshima University Verwendung von PDGF-R-Inhibitoren zur Behandlung der Lymphknotenmetastasen von Magenkrebs
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
WO2012014127A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
EP2648519A4 (de) * 2010-11-26 2014-04-30 Hetero Research Foundation Neues polymorph von nilotinib-hydrochlorid
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
SG11201401476TA (en) 2011-11-14 2014-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2802314B1 (de) 2012-01-13 2020-11-25 XSpray Microparticles AB Verfahren zur herstellung stabiler, amorpher hybrider nanopartikel mit mindestens einem proteinkinaseinhibitor und mindestens einer polymeren stabilisierungs- und matrixformungskomponente
IN2014DN10801A (de) 2012-07-11 2015-09-04 Novartis Ag
US9376419B2 (en) 2012-10-15 2016-06-28 Apotex Inc. Solid forms of nilotinib hydrochloride
US9567317B2 (en) 2012-10-19 2017-02-14 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
EP2792360A1 (de) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
JP2016522182A (ja) 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
EP3189045B1 (de) * 2014-08-11 2022-02-09 Sun Pharmaceutical Industries Limited Neuartige salze von nilotinib und deren polymorphe formen
EP3271351A1 (de) 2015-03-20 2018-01-24 Cipla Limited Neuartige polymorphe form x von nilotinibdihydrochloridhydrat
WO2017129694A1 (en) 2016-01-26 2017-08-03 Farma Grs, D.O.O. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
US10640487B2 (en) 2016-03-14 2020-05-05 Teva Pharmaceuticals Usa, Inc. Solid state forms of Nilotinib salts
EP3404025B1 (de) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Verfahren zur herstellung von reinem nilotinib und seinen salzen
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
EP4096791A1 (de) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphe nilotinib-mikropartikel und deren verwendungen
US20230075170A1 (en) * 2020-02-15 2023-03-09 Cipla Limited Novel salts of nilotinib and polymorphic forms thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
EP4260848A1 (de) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmazeutische zusammensetzung für eine feste dosierungsform, die nilotinib enthält, und verfahren zu ihrer herstellung
EP4642435A1 (de) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Pharmazeutische suspension von nilotinib
US12419892B2 (en) 2023-11-08 2025-09-23 Xspray Pharma Ab Pharmaceutical compositions comprising nilotinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2081108C1 (ru) * 1991-10-16 1997-06-10 Циба-Гейги АГ Аддитивные соли кислот с основанием и фармацевтическая композиция, обладающая противоопухолевой активностью
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PT672041E (pt) 1993-10-01 2002-04-29 Novartis Ag Derivados da piridina farmacologicamente activos e processos para a sua preparacao
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1238974B1 (de) * 1999-12-14 2007-05-23 Nippon Shinyaku Co., Ltd. Heterocyclische derivate und arzneistoffe
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
PE20051096A1 (es) * 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
SA06270147B1 (ar) * 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
EP1910336A1 (de) 2008-04-16
NZ591142A (en) 2012-09-28
CN102267981A (zh) 2011-12-07
US20120270891A1 (en) 2012-10-25
UY29683A1 (es) 2007-02-28
AU2006276205B2 (en) 2010-08-19
US20140038994A1 (en) 2014-02-06
HK1116778A1 (en) 2009-01-02
AU2010241419B2 (en) 2012-03-29
PL1910336T3 (pl) 2011-11-30
US20080200487A1 (en) 2008-08-21
KR20140047737A (ko) 2014-04-22
KR20150100946A (ko) 2015-09-02
RU2013101749A (ru) 2014-07-27
KR20080027855A (ko) 2008-03-28
US8389537B2 (en) 2013-03-05
TW200800950A (en) 2008-01-01
AU2006276205A1 (en) 2007-02-08
AU2010241419A1 (en) 2010-12-02
IL187787A (en) 2012-07-31
RU2434864C2 (ru) 2011-11-27
RU2605551C2 (ru) 2016-12-20
IL187787A0 (en) 2008-08-07
EP1910336B1 (de) 2011-06-29
CY1111772T1 (el) 2015-10-07
KR101755137B1 (ko) 2017-07-06
HRP20110639T1 (hr) 2011-10-31
EP2186808A1 (de) 2010-05-19
DK1910336T3 (da) 2011-10-03
SG170772A1 (en) 2011-05-30
CA2615669C (en) 2013-11-12
NO341313B1 (no) 2017-10-09
PT1910336E (pt) 2011-09-05
AR057467A1 (es) 2007-12-05
PE20070241A1 (es) 2007-03-22
JO2757B1 (en) 2014-03-15
JP5129132B2 (ja) 2013-01-23
US8580806B2 (en) 2013-11-12
ECSP088118A (es) 2008-02-20
EP2186808B1 (de) 2017-04-19
US8163904B2 (en) 2012-04-24
GT200600316A (es) 2007-04-02
MY149889A (en) 2013-10-31
RU2483065C2 (ru) 2013-05-27
NO20080897L (no) 2008-02-20
MA29686B1 (fr) 2008-08-01
CA2823946A1 (en) 2007-02-08
TWI455934B (zh) 2014-10-11
BRPI0613605A2 (pt) 2011-01-18
US20130137712A1 (en) 2013-05-30
ES2634291T3 (es) 2017-09-27
JP2009502796A (ja) 2009-01-29
AU2010241419C1 (en) 2024-05-23
US9163005B2 (en) 2015-10-20
CA2823946C (en) 2015-12-29
SI1910336T1 (sl) 2011-10-28
CA2615669A1 (en) 2007-02-08
RU2011120363A (ru) 2012-11-27
RU2008105827A (ru) 2009-08-27
RU2509767C1 (ru) 2014-03-20
AU2006276205C1 (en) 2024-08-01
WO2007015871A1 (en) 2007-02-08
NZ564182A (en) 2011-03-31
MX2008000892A (es) 2008-03-18
TNSN08028A1 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
ATE514689T1 (de) 4-methyl-n-ä3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenylü-3-(4-pyridin-3-yl- pyrimidin-2-ylamino)-benzamid- monohydrochlorid- monohydrat-salz
FIC20240003I1 (fi) Gadopiklenoli
DE602005020856D1 (de) Unterhose
EP1775630A4 (de) Tasche
DE602005011440D1 (de) Höhenmessuhr
EP1917541A4 (de) Kombination aus strahlungsdosimeter und ratenmesser
DK1683933T3 (da) Betjeningsgreb
DE602006019046D1 (de) Türschliesservorrichtung
DE602006012553D1 (de) Jektionsformung
DE602006015580D1 (de) Anti-Verkokungsinjektorarm
DE602006021785D1 (de) Oberflächenrauhigkeitsprüfer
DE602006017100D1 (de) Luftgurtvorrichtung
EP1905864A4 (de) In-sm-oxid-sputtertarget
DE602006007892D1 (de) Ionomermembran
DE602005023501D1 (de) Radhausbau
DE602005021060D1 (de) Notrufleitweglenkung
DE502005005839D1 (de) Feldgeerät
ATA7602005A (de) Antimykotikum
EP1942979A4 (de) Atemwegsballondilatator
FI20055434A0 (fi) Reftraktometri
DE602006014330D1 (de) Klipsstützträger
DE502006006589D1 (de) Teils
EP1852165A4 (de) Modellauto
DE602005008023D1 (de) Originalitätssprühkappe
DE602006007505D1 (de) Plamaanzeigetafel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1910336

Country of ref document: EP